ライフサイエンスコーパス: ISS

1 ISS adopts a stable structure consisting of conserved UG

2 ISS application significantly increased survival rates o

3 ISS consists of an ingestible event marker (IEM), a micr

4 ISS could detect accurately the ingestion of two IEM-ECM

5 ISS DNA induces intestinal expression of IDO-1 but not t

6 ISS Expedition-9 crewmembers attended a 2.5-hour didacti

7 ISS inhibits the Th2 response by rendering lung antigen-

8 ISS is a promising new technology that provides highly r

9 ISS reduced bronchoalveolar lavage and lung levels of TG

10 ISS, CA, and LDH data were simultaneously available in 3

11 responded to intranasally administered 1018 ISS, a representative B class ISS, with strictly TLR9-de

12 evaluating 4 dose levels of a CpG-ODN (1018 ISS) with rituximab in 20 patients with relapsed non-Hod

13 1063 in-flight days) and 21 astronauts on 13 ISS missions (3248 in-flight days), with ground-based da

14 g on 500 (52%) of 963 nights; 12 (75%) of 16 ISS crew members reported using sleep-promoting drugs.

15 We analyzed the intron 7 ISS by mutagenesis, coupled with splicing assays, RNA-af

16 Although mast cells express TLR-9, ISS does not directly inhibit mast cell proliferation in

17 In addition, ISS significantly reduces lung levels of expression of t

18 ocalorimetry, in combination with LEED, AES, ISS, work function, sticking probability measurements, a

19 he lamina propria, which also increase after ISS-oligodeoxynucleotide.

20 evaluated a morpholino (MO) oligomer against ISS-N1 [HSMN2Ex7D(-10,-29)], and delivered this MO to po

21 ISS-N1, an antisense oligonucleotide against ISS-N1 restored exon 7 inclusion in mRNAs derived from t

22 from cardiac uncoupling and covariates (age, ISS, AIS Head Score, total transfusion requirements) was

23 n the non-TGC group when controlled for age, ISS, obesity, and diabetes (P<0.01).

24 used 82 (77%) of these infections and had an ISS calculated.

25 n 24 (0.4%) of 5,665 trauma patients with an ISS of 0-19, as compared with six (5.0%) of 122 patients

26 ared with six (5.0%) of 122 patients with an ISS of 40 or higher.

27 ism of injury, hypotension on admission, and ISS (< or =25 and >25).

28 On the basis of AES and ISS measurements, it was determined that Ca grows mainly

29 C mixtures was further enhanced by CD40L and ISS-ODN treatment.

30 H), EMC92, and UAMS70 (GEP classifiers), and ISS.

31 s signaling in response to bacterial DNA and ISS-ODN has not been identified.

32 The ISM and ISS form a bipartite regulatory element, within which th

33 on performing surgical exploration, PVL, and ISS results in a marked and rapid hypertrophy of functio

34 prevalent not only during space shuttle and ISS missions, but also throughout a 3 month preflight tr

35 Analysis of authentic ISS water samples using the ETV-AQM showed that DMSD cou

36 Time-averaged ISS (ISSave) in the thoracic aorta also increased in the

37 A CpG-B ISS-ODN increased CD80/CD86 expression by PDCs, but resu

38 th DTP3 coverage of 65% or less at baseline, ISS spending per surviving child had a significant posit

39 Because ISS funding seems to have no effect in countries with ba

40 d tomographic volumetry was performed before ISS and before completion surgery.

41 priming ability of PDCs already activated by ISS.

42 owth in vitro was significantly inhibited by ISS-ODN treatment of human and mouse macrophages, and M.

43 Thus, inhibition by ISS of allergic responses can be explained by two novel

44 The CpG-C ISS-ODN also stimulated IL-12 release (unlike AT-2 SIV)

45 In contrast, a CpG-C ISS-ODN and aldrithiol-2-inactivated (AT-2) SIV induced

46 We have shown that the CpG-C ISS-ODN C274 stimulates macaque blood dendritic cells (D

47 fected macaques, revealing a promising CpG-C ISS-ODN-driven DC activation strategy that boosts immune

48 tivities, supporting the potential for CpG-C ISS-ODNs to boost immune function to enhance anti-HIV va

49 inistered 1018 ISS, a representative B class ISS, with strictly TLR9-dependent toxicity, including lu

50 We conducted ISS by monitoring patients with influenza-like illness (

51 structure of the phylogenetically conserved ISS stem loop.

52 In contrast, ISS inhalation has unexplained toxicity in rodents, whic

53 ay offer unique advantages over conventional ISS because identification of the optimal motifs, spacer

54 ncrease in mean ISS between cohorts (pre-DCR ISS = 23 vs DCR ISS = 27; P < .05) and a marked shift in

55 ISS between cohorts (pre-DCR ISS = 23 vs DCR ISS = 27; P < .05) and a marked shift in injury patterns

56 activation of TLR9 by immunostimulatory DNA (ISS-ODN), induces a prominent Th2-biased immune response

57 whether immunostimulatory sequences of DNA (ISS) can reverse established airway remodeling, mice tha

58 all models, but the augmented TMPM dominated ISS by every measure [ROCTMPM = 0.925(0.921-0.928), ROCI

59 ides targeting either upstream or downstream ISS elements increased alpha-exon inclusion from 10% up

60 nstrated the feasibility of integrating EIS, ISS, and IVUS for a catheter-based approach to assess me

61 The EMC92-ISS classification is a novel prognostic tool, based on

62 g risk classifications showed that the EMC92-ISS combination is the strongest predictor for overall s

63 itor of many of the activities described for ISS, and this may impact the use of ISS in disease state

64 The optimal cut-off for ISS was 33, with sensitivity of 60.0%, specificity of 80

65 oll-like receptor-9 (TLR-9; the receptor for ISS), TLR-9 expression by mouse bone marrow-derived mast

66 Furthermore, ISS function is location-independent but requires proxim

67 GAVI ISS significantly increased the difference between offic

68 d from surveys at a rate of US$20 each, GAVI ISS payments are estimated at $150 million (115 million

69 dependent variable and the presence of GAVI ISS as the independent variable, controlling for country

70 Up to 2006, in 51 countries receiving GAVI ISS payments, 7.4 million (5.7 million to 9.2 million) a

71 in all but the most severely injured group (ISS > 40).

72 ds (CICs), which contain multiple heptameric ISS connected by non-nucleoside spacers in both linear a

73 ation of multiple copies of these heptameric ISS with free 5'-ends via long, hydrophilic spacers, suc

74 3) triggered more prompt transfer, but high ISS was underappreciated and did not result in a prompt

75 In the high-ISS category (51-75) (n = 75; 4.6%), time to operation w

76 TBI patients had normal neuroimaging, higher ISS, and comparable LOS to TBI-negative patients.

77 he Lyon center received patients with higher ISS, lower Glasgow Coma Score (GCS), and lower systolic

78 ociated with higher APACHE II scores, higher ISSs, and previous carbapenem antibiotics in comparison

79 If ISS expenditure only is assessed, the estimated cost per

80 line coverage of 65% or less is US$14 and if ISS and non-ISS expenditures are included the cost per c

81 IDO-1 by a TLR-9 agonist, immunostimulatory (ISS) DNA, critically contributes to its colitis limiting

82 ognosis and chemotherapy sensitivity (eg, in ISS stage I, one cluster was characterized by increased

83 l shedding also was significantly reduced in ISS-treated animals (P < 0.001).

84 ntly more sensitive to ethanol than those in ISS neurons.

85 ormal range); R-ISS III (n = 295), including ISS stage III (serum beta2-microglobulin level > 5.5 mg/

86 : revised ISS (R-ISS) I (n = 871), including ISS stage I (serum beta2-microglobulin level < 3.5 mg/L

87 sputum of allergic humans exposed to inhaled ISS demonstrated induction of IFN-inducible genes but mi

88 ity of patients (74%) were severely injured (ISS > 15), and 80% died within 24 hours of admission.

89 Score (ISS) to classify 84 severely injured (ISS > or =9), 309 non-severely injured (ISS 1-8), and 18

90 red (ISS > or =9), 309 non-severely injured (ISS 1-8), and 189 uninjured (ISS 0) pregnant women and c

91 ith those of 6 patients with minor injuries (ISS </= 4).

92 group, sex, Revised Trauma Score, and injury ISS, ICP monitoring was associated with a reduction in m

93 Silencing of exon IIIc splicing by ISE/ISS-3 was shown to require a branch point sequence (BPS)

94 IIIb; hence, we have termed this element ISE/ISS-3 (for "intronic splicing enhancer-intronic splicing

95 gulated by the auxiliary RNA cis-element ISE/ISS-3 that promotes splicing of exon IIIb and silencing

96 ) binds the FGFR-2 auxiliary cis-element ISE/ISS-3, located in the intron between exon IIIb and IIIc,

97 reviously identified an RNA cis-element, ISE/ISS-3, that enhanced exon IIIb splicing and silenced exo

98 ation of relative functional activity of ISE/ISS-3 mutants using flow cytometric analysis of live cel

99 second step of splicing suggesting that ISE/ISS-3 may block exon IIIc inclusion at this step.

100 splicing regulatory factor that binds to ISE/ISS-3 in a sequence-specific manner.

101 udes it, and association of hnRNP M with ISE/ISS-3 was shown to contribute to this splicing regulator

102 expressed TLR-9 and bound rhodamine-labeled ISS.

103 casualties (n = 1054; 61.2%) were in the low-ISS (1-15) bracket in which there was no difference in e

104 ation, and 6.7% (32/480) in ILI with maximum ISS > 2.

105 4%; P <.001, chi(2) test) and a higher mean ISS (25.2 vs 9.7; P <.01, t test).

106 There was a significant increase in mean ISS between cohorts (pre-DCR ISS = 23 vs DCR ISS = 27; P

107 ating both groups) and injury severity (mean ISS faculty 10.0; FIEs 9.5).

108 The mean ISS for each S. aureus clone (based on MLST) was compare

109 Patients had a median ISS of 17 with 72% suffering from blunt injury.

110 propose an in silico gene sequencing method (ISS), which predicts phased sequences of intragenic regi

111 Casualties in the mid-ISS bracket (16-50) (n = 583; 33.4%) experienced the sam

112 In this mid-ISS bracket, mortality was lower in the AMR than in the

113 t targets the intronic splicing silencer N1 (ISS-N1), located downstream of the 5' splice site (5'ss)

114 this element intronic splicing silencer N1 (ISS-N1).

115 that we term intronic splicing silencer N2 (ISS-N2).

116 CONCLUSION) The new ISS is simple, based on easy to use variables (Sbeta2M a

117 immunisation services support (ISS) and non-ISS expenditure per surviving child, controlling for inc

118 e of 65% or less is US$14 and if ISS and non-ISS expenditures are included the cost per child is almo

119 For comparison, groups of untreated, non-ISS oligonucleotide-treated, and acyclovir-treated anima

120 f HSV-2 lesions compared to results with non-ISS oligonucleotide-treated and untreated guinea pigs (P

121 tiation of distal GABAA IPSCs in ILS but not ISS mice, and this blockade of GABAB receptor function h

122 The second important action of ISS is inhibition of immunoglobulin E-dependent release

123 As the activities of ISS on PDCs are central to many clinical applications of

124 A single administration of ISS (21 days after viral inoculation) significantly redu

125 Systemic administration of ISS to mice that had already developed established airwa

126 lass II on CD11c(+ )APCs from the airways of ISS-treated mice.

127 cated that vaginal epithelial application of ISS (up to 6 h after viral inoculation) with mice lethal

128 are central to many clinical applications of ISS, we have studied the effects of IL-10 on PDC stimula

129 The 3 distinct classes of ISS differed with respect to induction of PDC maturation

130 on PDC stimulation by 3 distinct classes of ISS.

131 Deletion of ISS-N1 promoted exon 7 inclusion in mRNAs derived from t

132 Here, we demonstrate that airway delivery of ISS before allergen challenge in Th2-primed mice acts in

133 required for the antimycobacterial effect of ISS-ODN.

134 s inhibited, the colitis limiting effects of ISS-oligodeoxynucleotide were abrogated.

135 Confirming the silencer function of ISS-N1, an antisense oligonucleotide against ISS-N1 rest

136 The implementation of ISS enabled characterization of the epidemiology and sea

137 As an additional indication of ISS efficacy, the magnitude of viral shedding also was s

138 oped the first viable genetic mouse model of ISS that spontaneously recapitulates salient phenotypic

139 Underlining the dominant role of ISS-N1 in exon 7 skipping, abrogation of a number of pos

140 e to the differential ethanol sensitivity of ISS and ILS mice.

141 1 pyramidal neurons in hippocampal slices of ISS and ILS mice indicate that ethanol enhances GABAA re

142 The success of ISS funding in countries with baseline DTP3 coverage of

143 nhibited cytokine production and survival of ISS-activated PDCs; however, IL-12 induction was much mo

144 ibed for ISS, and this may impact the use of ISS in disease states characterized by elevated IL-10.

145 stimulatory CpG-C oligodeoxyribonucleotides (ISS-ODNs) represent a promising strategy to enhance vacc

146 immunostimulatory oligodeoxyribonucleotides (ISS-ODNs)) is crucial for maximal stimulation of innate

147 cell activity was predominantly dependent on ISS motif, with 5'-TCGTXXX and 5'-AACGTTC being the most

148 363 patients, respectively, were matched on ISS stage and LDH.

149 Crew members on ISS missions obtained significantly less sleep during sp

150 Saturated BLAST is a package that performs ISS in an efficient and automated manner.

151 L) and high-risk CA or high LDH level; and R-ISS II (n = 1,894), including all the other possible com

152 d the following three groups: revised ISS (R-ISS) I (n = 871), including ISS stage I (serum beta2-mic

153 ess than the upper limit of normal range); R-ISS III (n = 295), including ISS stage III (serum beta2-

154 months, the 5-year OS rate was 82% in the R-ISS I, 62% in the R-ISS II, and 40% in the R-ISS III gro

155 OS rate was 82% in the R-ISS I, 62% in the R-ISS II, and 40% in the R-ISS III groups; the 5-year PFS

156 ISS I, 62% in the R-ISS II, and 40% in the R-ISS III groups; the 5-year PFS rates were 55%, 36%, and

157 The R-ISS is a simple and powerful prognostic staging system,

158 nt differences in overall complication rate (ISS, 48 [34.5%]; ELM, 37 [27.2%]; P = .19) and mortality

159 LM, 37 [27.2%]; P = .19) and mortality rate (ISS, 10 [7.2%]; ELM, 6 [4.4%]; P = .32) were found.

160 defined the following three groups: revised ISS (R-ISS) I (n = 871), including ISS stage I (serum be

161 P < 0.0001), a higher Injury Severity Score (ISS 5 +/- 8 vs. 9 +/- 11, P < 0.0001), and a higher inci

162 to severely injured [injury severity score (ISS) > 8] adult patients (age >/= 16) presenting alive t

163 years of age and had injury severity score (ISS) >15, were alive on admission and had at least one o

164 imum daily influenza symptom severity score (ISS) >2.

165 AN group had a higher Injury Severity Score (ISS) (17.5 versus 11.0, P < 0.05), lower Glasgow Coma Sc

166 44 vs. 43 years), and Injury Severity Score (ISS) (26 vs. 25).

167 (APACHE II) score or injury severity score (ISS) and previous antibiotic use.

168 from baseline in weekly itch severity score (ISS) at week 12.

169 pared per incremental Injury Severity Score (ISS) bins.

170 as used to derive an illness severity score (ISS) from clinical data, including 30-day mortality, req

171 c brain injury (TBI), Injury Severity Score (ISS) greater than 9, and Glasgow Coma Scale (GCS) score

172 75 males) with a mean injury severity score (ISS) of 24 (range 9-66), from whom blood samples were ac

173 he negative impact of injury severity score (ISS) on mortality (P = 0.071).

174 They used the Injury Severity Score (ISS) to classify 84 severely injured (ISS > or =9), 309

175 The median injury severity score (ISS) was 13 (interquartile range [IQR] 9-22).

176 Higher Injury Severity Score (ISS) was associated with abnormal neuroimaging, longer l

177 Mean age, injury severity score (ISS), and APACHE score were 43 +/- 20 years, 29 +/- 13,

178 Injury severity score (ISS), associated injury, and patient outcome data were g

179 al trauma, and higher Injury Severity Score (ISS).

180 vs. 30 +/- 8 years), Injury Severity Score (ISS; 12 +/- 11 vs. 12 +/- 11), systolic blood pressure i

181 lly injured patients (Injury Severity Score [ISS] >/= 25) at The Royal London Hospital in the hyperac

182 nts (n = 472, average injury severity score [ISS] = 20.2) exhibited elevations in plasma IL33 levels

183 3 years of age) with Injury Severity Scores (ISS) 36.6 +/- 13.9 on days 1 and 7 after trauma and from

184 Injury types and Injury Severity Scores (ISSs), timing and location of death, and initial (24-hou

185 G-containing immunostimulatory DNA sequence (ISS) given before allergen challenge can inhibit T helpe

186 istration of two immunostimulatory sequence (ISS)-containing phosphorothioate-stabilized oligonucleot

187 we targeted the intronic silencing sequence (ISS) elements flanking the alternatively spliced alpha-e

188 Immunostimulatory DNA sequences (ISS) containing CpG motifs induce interferon-alpha (IFN-

189 containing immunostimulatory DNA sequences (ISS) with nonmethylated CpG dinucleotides in a defined m

190 -containing immunostimulatory DNA sequences (ISS), which signal through TLR9, are being developed as

191 Immunostimulatory sequences (ISS) are short oligonucleotides containing unmethylated

192 ating mice with immunostimulatory sequences (ISS) of DNA containing a CpG motif significantly inhibit

193 n the presence of other variables (age, sex, ISS, Revised Trauma Score, and GCS score) was associated

194 otif of the human intronic splicing silencer ISS-N1, which controls survival of motor neuron exon 7 s

195 directed against an intron splice silencer (ISS) in the survival motor neuron 2 (SMN2) gene alter th

196 We identify an intronic splicing silencer (ISS) adjacent to the M1 branch point that is sufficient

197 treatment to SMN2 intron7-splicing silencer (ISS) improves SMN expression and motor function.

198 plice site, and an intron splicing silencer (ISS) within intron 10 (I10).

199 ex network of an intronic splicing silencer (ISS), a bipartite exonic splicing silencer (ESS3a/b), an

200 ers (ISEs), and intronic splicing silencers (ISSs), which are typically located near the splice sites

201 identified two intronic splicing silencers (ISSs): one in intron 6 and a recently described one in i

202 peared to be immunologically mediated, since ISS had no direct effect on HSV-2 replication in vitro u

203 sensitivity by utilizing inbred short sleep (ISS) and inbred long sleep (ILS) mouse strains that disp

204 e intrahepatic, small (<7 cm), and solitary (ISS) and those that had extrahepatic extension and were

205 low-energy He+ ion scattering spectroscopy (ISS).

206 vein ligation (PVL), and in situ splitting (ISS) of the liver parenchyma along the falciform ligamen

207 nonsurvivors than does the current standard, ISS.

208 truction of the International Space Station (ISS) and the subsequent extension in mission duration up

209 or assigned to International Space Station (ISS) expeditions between Sept 18, 2006, and March 16, 20

210 The International Space Station (ISS) experiment TRIPLE LUX A, performed in the BIOLAB la

211 ironment on the International Space Station (ISS) includes a variety of potential physiologic stresso

212 n-flight on the International Space Station (ISS), and benchmarked its performance off-Earth against

213 ance aboard the International Space Station (ISS).

214 x months on the International Space Station (ISS).

215 -treated boys with idiopathic short stature (ISS) had no loss of bone density but were noted to have

216 vascular ultrasound (IVUS) and shear stress (ISS) provided a new strategy to assess oxLDL-laden lesio

217 Regarding MM, we subclassified ISS stages into clusters based on shared features of tum

218 The Cassini Imaging Science Subsystem (ISS) began observing Saturn in early February 2004.

219 ns by the Cassini Imaging Science Subsystem (ISS) during the first 9 months of Cassini operations at

220 rammetry on Cassini Image Science Subsystem (ISS) images, we measured longitudinal physical forced li

221 s acquired by the Imaging Science Subsystem (ISS), this region is circumscribed by a chain of folded

222 5 to 2004 and immunisation services support (ISS) and non-ISS expenditure per surviving child, contro

223 CI and GAVI's immunisation services support (ISS) might encourage over-reporting.

224 ablished an influenza sentinel surveillance (ISS) system to describe the epidemiology of influenza an

225 Infantile spasms syndrome (ISS) is a catastrophic pediatric epilepsy with motor spa

226 arthritis but could be replaced by synthetic ISS oligodeoxynucleotides.

227 he accuracy of the Ingestible Sensor System (ISS), a novel technology for directly assessing the inge

228 e superior for International Staging System (ISS) stage 1 disease, when lactate dehydrogenase (LDH) l

229 e status of 1, International Staging System (ISS) stage of 1, and Durie-Salmon stage of IIIA.

230 ) adjusted for International Staging System (ISS) stage.

231 , and subgroup International Staging System (ISS) stages into more prognostically accurate clusters o

232 This new International Staging System (ISS) was validated in the remaining patients and consist

233 e combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by int

234 Here, International Staging System (ISS), fluorescence in situ hybridization (FISH) markers,

235 Overall, these studies demonstrate that ISS can reverse features of airway collagen deposition b

236 These data demonstrate that ISS induce rodent-specific TNF-alpha-dependent toxicity

237 In vitro studies demonstrated that ISS inhibited TGF-beta1 expression by macrophages (RAW 2

238 novel risk classifications demonstrated that ISS is a valuable partner to GEP classifiers and FISH.

239 Knockout mouse experiments demonstrated that ISS-induced toxicity was critically dependent on TNF-alp

240 These data suggest that ISS may be useful in the treatment and control of genita

241 cell proliferation in vitro, suggesting that ISS inhibits accumulation of peribronchial mast cells in

242 The ISS also contains a consensus binding site for Rbp1, and

243 The ISS also impacted an established infection in the guinea

244 The ISS cutoff less than 33 may be useful in the selection p

245 The ISS has served as the standard measure of anatomic injur

246 The ISS oligonucleotides, suspended in phosphate-buffered sa

247 The ISS sequence extends from I10 nucleotides 11-18, which i

248 The ISS system was further validated by demonstrating effect

249 The ISS was found to function independently of its position

250 ne sequencing runs were performed aboard the ISS over a 6-month period, yielding a total of 276,882 r

251 Aboard the ISS, they completed a 1-hour computer-based Onboard Prof

252 From sequence data collected aboard the ISS, we constructed directed assemblies of the 4.6 Mb E

253 ysis and microbial identification aboard the ISS.

254 transfer sensor was deployed to acquire the ISS profiles at baseline and post high-fat diet (HD) in

255 neous nuclear ribonucleoprotein A1 binds the ISS apical loop site-specifically and with nanomolar aff

256 is present, mitigating E10 repression by the ISS.

257 before, during and after their stays in the ISS; hereafter, referred to as Preflight, Inflight and P

258 was identified immediately downstream of the ISS at I10 positions 19-26.

259 A, performed in the BIOLAB laboratory of the ISS COLUMBUS module, allowed for the first time the dire

260 Simultaneous targeting of the ISS elements had no additive effect, suggesting that spl

261 was demonstrated by similar targeting of the ISS elements of the human hnRNPA1 gene.

262 is-promoting effect of the Mtb DNA or of the ISS oligodeoxynucleotides correlated with an increased T

263 need to study new exercise programmes on the ISS that employ high resistance and contractions over a

264 The most frequently used medications on the ISS were for sleep problems, pain, congestion, or allerg

265 The TMPM should replace the ISS as the standard measure of overall injury severity.

266 y of routine sequencing of all subjects, the ISS method proposed here provides a time- and cost-effec

267 experimental therapeutics have targeted the ISS-N1 element of SMN2 pre-mRNA, the development of E1 A

268 survivors from nonsurvivors better than the ISS, but one, the trauma mortality prediction model (TMP

269 58 (35-91), HLISS = 296 (228-357)] than the ISS.

270 Thus, the ISS functions as a linear sequence.

271 cer, we found that Rbp1 and Tra2 bind to the ISS independently through distinct sequences.

272 ent, within which the ISM functions when the ISS is present, mitigating E10 repression by the ISS.

273 odels and compare their performance with the ISS using measures of discrimination (C statistic), cali

274 L) genes did not directly correlate with the ISS, being present in the second, fourth, and 10th most

275 ation and calibration when compared with the ISS.

276 und two tandem hnRNP A1/A2 motifs within the ISS that are responsible for its inhibitory character.

277 Furthermore, both binding sites within the ISS-N1 are important for splicing repression and their c

278 data defined elements of function within the ISSs flanking exon IIIb and suggested that silencing of

279 The Ca here is invisible to ISS, which is attributed to Ca binding to ester groups b

280 the PDC population are cells that respond to ISS by producing either IL-12 or IFN-alpha but not both

281 ppreciable TNF-alpha in vitro in response to ISS stimulation.

282 o inhibit a complex pathological response to ISS, as shown by protection from death after massive sys

283 formation or mRNA transport and translation, ISS-N1 provides a very specific and efficient therapeuti

284 verely injured (ISS 1-8), and 189 uninjured (ISS 0) pregnant women and compared them with pregnant wo

285 erence response (5-point decrease) in weekly ISS (P<0.0001) and higher percentages of patients with w

286 Compared with placebo (n=80), mean weekly ISS was reduced from baseline to week 12 by an additiona

287 subcutaneously every 4 weeks reduced weekly ISS and other symptom scores versus placebo in CIU/CSU p

288 of positive cis elements was tolerated when ISS-N1 was deleted.

289 BALB/c splenocytes, A20 cells activated with ISS-ODN and then transduced with Ad-CD154 were significa

290 The volume of trauma admissions with ISS >15 (<240 vs > or =240 cases per year) had no effect

291 ma (<240 vs > or =240 trauma admissions with ISS >15 per year).

292 ult height in pre and peripubertal boys with ISS when re-assessed 4 years after the treatment period.

293 Treatment of A20 cells with ISS-ODN also enhanced surface expression of alphav integ

294 lecules on A20 cells, as did incubation with ISS-ODN.

295 However, incubation of MBMMCs with ISS in vitro neither inhibited MBMMC proliferation nor i

296 Also, injection of mice with ISS-activated, Ad-CD154-infected cells induced significa

297 repetitive OVA challenges, were treated with ISS for 1-3 mo.

298 y more effective than A20 cells treated with ISS-ODN alone.

299 larly inhibited in C57BL/6 mice treated with ISS-ODN.

300 us (Ad) encoding CD154 and/or treatment with ISS-ODN could enhance the capacity of A20 murine B lymph